60 results about "Ketone bodies" patented technology

The present invention employs a cleaning liquid containing a solvent and a metal remover. In the cleaning liquid, two or more solvents are included, the distance (HSP distance) between the Hansen solubility parameter of the cleaning liquid and the Hansen solubility parameter of dimethylacetamide is 1.0 or less, and the total content of an organic substance selected from the group consisting of organic acid multimers, organic acid esters, and ketone bodies is 0.1 × 10-9 parts by mass or more and 105 × 10-6 parts by mass or less with respect to 100 parts by mass of the total of the solvent and the metal remover. This cleaning liquid improves removal of organic impurities.

Provided are methods for treating a disease or condition associated with reduced autophagy in a patient, which includes administering to the patient, either simultaneously or sequentially, a therapeutically effective amount of a synergistic combination of compounds from at least two and preferably three of the classes of compounds selected from a saccharide, a vitamin, a ketone body, a polyphenol, and a methylxanthine. The compounds may be present in a subtherapeutic effective amount relative to the compound's dosing when given as a single agent. Also provided are pharmaceutically acceptable compositions and kits including at least two and preferably three of the named classes of compounds.

The present application relates to an extracorporeal blood treatment system (50) for treating a subject, the system comprising: an extracorporeal blood circuit (52); a dialysate fluid circuit (54); the extracorporeal blood circuit and the dialysate fluid circuit being separated by a membrane (56) of a filtration unit (58); at least one blood pump (60) for controlling the flow of blood through the blood circuit; at least one dialysate fluid pump (62) for controlling the flow of dialysate fluid through the dialysate fluid circuit (54); a system computing unit (64) operatively connected to the blood pump and to the dialysate fluid pump, the system computing unit having at least one input; wherein the system computing unit is adapted to receive a desired blood concentration of glutamine GLN b , to receive a desired blood concentration of glucose GLUCOSE b , and to receive a desired blood concentration of ketone bodies KETONE b ; the system computing unit being adapted to control the blood pump and the dialysate fluid pump such that an actual concentration value of glutamine GLN a is driven to approach GLN b , and an actual concentration value of glucose GLUCOSE a is driven to approach D b , and an actual concentration value of ketone bodies is driven to approach KETONE a . The present application relates to a treatment device for use in an extracorporeal blood treatment system, a method for treating cancer using the system, a controller for controlling the method and a dialysis liquid suitable for use in the method.

The invention belongs to the field of drug delivery, and particularly relates to a glucose and ketone body dual-response long-acting insulin delivery system as well as a preparation method and application thereof. The glucose and ketone body dual-response long-acting insulin delivery system provided by the invention comprises a drug crystal, a polymer coating wrapping the drug crystal and a phenylboronic acid based cationic polymer modified in the polymer coating. The long-acting insulin can prolong the treatment time of the glucose-responsive insulin delivery carrier, meanwhile, the glucose-responsive insulin delivery carrier has a ketone body response behavior, ketoacidosis is inhibited, and the problems that an existing glucose-responsive insulin delivery carrier is short in treatment time, a ketone body-responsive insulin delivery carrier is difficult to construct and the like are solved.

The invention belongs to the technical field of formula foods for special medical purposes, and particularly relates to a fat component for treating Alzheimer's disease and a preparation method of the fat component. The fat component is prepared from the following raw materials in parts by weight: medium-chain triglyceride, starch sugar, silicon dioxide, sodium caseinate, starch sodium octenylsuccinate, mono-glycerol fatty acid ester, diglycerol fatty acid ester and potassium hydroxide. And a neuroprotective nutrient combination. According to the invention, the medium-chain triglyceride capable of supplying energy quickly is creatively combined with the nerve protection nutrient with a specific mechanism. The medium-chain triglyceride provides efficient ketone energy; magnesium citrate stabilizes the excitability of neurons; the nicotinamide ribose supports cell energy metabolism; the omega-3 fatty acid plays roles in resisting inflammation and repairing nerve cell membranes. The four components provide protection from energy supply, neuron stabilization, metabolism support and structure repair, and bring better neurological function prognosis while controlling the Alzheimer's disease.

Disclosed are a system, techniques and processes for monitoring and modifying a drug treatment regimen when a user partakes in a ketogenic diet. The disclosed system obtains ketone level measurements of a user and indicates a user's adherence to the ketogenic diet as well as modifying a user's total daily dosage of a drug based on the user's following the ketogenic diet.

The invention relates to an intravenous micromodule with a multi-sensor architecture and an associated real-time decision support platform that enables continuous metabolic monitoring in the intravascular fluid phase. The system combines NIR spectroscopy, an electrochemical microprobe, a thermal flux sensor, and optical density analysis in a single compact IV module, providing real-time, uninterrupted, and highly accurate monitoring of the patient's metabolic status. The module measures critical parameters such as glucose, lactate, ketone bodies, electrolyte balance, and oxygenation in the intravascular fluid without requiring additional invasive procedures. Measurements are processed by the hybrid sensor fusion algorithm on the device, providing a low-latency data stream to the clinical decision support panel. The system detects metabolic disturbances with an early warning mechanism in scenarios such as emergency departments, intensive care units, operating rooms, and in-home chronic disease management.Unlike existing glucose monitors or single-parameter IV sensors, this invention presents the first hybrid architecture capable of monitoring multiple metabolic parameters simultaneously, continuously, and with high stability via the same vascular line. Furthermore, the dynamic liquid-phase referencing method developed for sensor calibration minimizes measurement drift during long-term use. This system offers significant advantages in areas such as early diagnosis of metabolic crises, treatment optimization, drug titration, and reduced clinical workload.

Embodiments of the invention provide amperometric analyte sensors having elements selected to optimize enzymatic activities associated with such sensors including polymers functionalized with enzymatic mediators as well as methods for making and using such sensors. While embodiments of the invention can be used in a variety of contexts, typical embodiments of the invention include glucose or ketone sensors used in the management of diabetes.

According to the invention, a cleaning solution containing a solvent and a metal remover is adopted. The cleaning solution contains two or more solvents, and the distance (HSP distance) between the Hansen solubility parameter of the cleaning solution and the Hansen solubility parameter of dimethylacetamide is 1.0 or less. The total content of an organic substance selected from the group consisting of an organic acid polymer, an organic acid ester, and a ketone body is from 0.1 * 10 <-9 > parts by mass to 105 * 10 <-6 > parts by mass (inclusive) per 100 parts by mass of the total of the solvent and the metal remover. According to the washing liquid, the removal performance of organic impurity dirt can be improved.

Disclosed are exemplary drug delivery systems that include controllers, drug delivery devices, and the like. The disclosed drug delivery system and controllers may include a processor, a user interface, a memory, and communication circuitry. An automated drug delivery algorithm is operable to receive a number of different inputs related to a user's glucose and / or ketone levels. The automated drug delivery algorithm(s) of the described drug delivery systems and controllers are operable to adjust to when a user partakes in fasting for a period of time that lasts a day or multiple days. The period of time may be a fasting event, such as a religious holiday or diet regimen. For example, the disclosed automated drug delivery algorithm(s) are operable to receive an indication of initiation of a fasting mode; and modify a drug delivery schedule based on the period of fasting or while in fasting mode.

The invention relates to a squid ketone body membrane removing device and method. The method comprises the steps of low-temperature softening, warm water relaxation, membrane removing, hydraulic stripping and liquid nitrogen rapid cooling. According to the device, the output end of a telescopic assembly is connected with a rotary drum through a rotary connector, an inner cavity of the rotary drum is connected with the output end of the rotary connector, the air input end of the rotary connector is connected with an external air source, and the inner cavity of the rotary drum is provided with a first push rod extending to the outside; the sex bag assembly comprises a fixing base, a shaft sleeve rotationally connected to the fixing base and an elastic sleeve with the open end connected with the shaft sleeve, the shaft sleeve is matched with the rotating drum, a spring is arranged in the elastic sleeve, and the outer diameter of the spring is gradually reduced from the side wall of the shaft sleeve; the rotating assembly is used for driving the drum to rotate; according to the squid body inner membrane removing device, the elastic bag assembly is driven by the telescopic assembly to be stuffed into the squid body, then the elastic bag assembly is inflated and expanded to be attached to the inner side wall of the squid body, and the inflated elastic bag assembly is driven by the rotating assembly to rotate to remove the inner membrane of the squid body.

Disclosed are a exhalation-type ketone measurement device and a measurement system.　An exhalation-type ketone measurement device according to one aspect of the present invention is compact and thus easy to carry, has a functional button and a display arranged in a row and thus has improved operability and visibility despite being compact, and is configured such that an inlet of an exhalation guide is shielded to increase hygiene when the device is not in use. A measurement system according to another aspect of the present invention is characterized in that the exhalation-type ketone measurement device and a smart communication device are linked, thus making it possible to continuously manage a user's health by using ketone measurement and analysis via an application.

Glucose and ketones may be dysregulated singularly or concurrently in certain physiological conditions and may be advantageously assayed together using an analyte sensor capable of detecting both analytes. Certain analyte sensors capable of dual detection may comprise a first working electrode and a second working electrode, a ketones-responsive active area disposed upon a surface of the first working electrode, a glucose-responsive active area comprising a glucose-responsive enzyme disposed upon a surface of the second working electrode, a membrane having a first portion overcoating the ketones-responsive active area and a second portion overcoating the glucose-responsive active area, in which the first portion and the second portion have different compositions. The ketones-responsive active area comprises an enzyme system comprising at least two enzymes that are capable of acting in concert to facilitate detection of ketones.

A system includes an analyte measurement system and a software application operatively coupled to the analyte measurement system. The analyte measurement system is configured to measure an analyte of a patient. The software application is configured to retrieve sensor data of the analyte level, analyte rate of change, or both; detect at least one condition associated with the sensor data; and provide a notification to the patient associated with the at least one detected condition. Advantageously the system can detect current or impending adverse conditions (such as an insulin deficiency), provide custom notifications (e.g., warnings, recommendations, guidance) to the patient to act, prompt the patient for additional information relevant to the detected condition, continuously monitor glucose and ketone levels in real-time, control insulin delivery based on ketone level, and mitigate the risk of euglycemic diabetic ketoacidosis (euDKA).

In various implementations, a composition comprising R-beta-hydroxybutyrate, related compounds, and / or one or more other compounds may be administered to an individual to cause weight loss, weight maintenance, elevate blood ketone levels, maintain blood ketone levels, reduce blood glucose levels, maintain blood glucose levels, improve energy, focus, mood, cognitive function, or aide with neurological or inflammatory disorders and / or combinations thereof. The composition may include sodium R-beta-hydroxybutyrate salts; potassium R-beta-hydroxybutyrate; and one or more other salts of R-beta-hydroxybutyrate.

A system is disclosed that monitors participants in health-related programs, such as weight loss or exercise programs, and that provides automated, personalized health coaching to the program participants. The system includes breath analysis devices that are used by the program participants to generate ketone measurements, and includes a mobile application that runs on mobile devices of the participants and communicates with corresponding breath analysis devices. The system operates generally by monitoring ketone levels (such as acetone levels) and other attributes of the participants and by making personalized, machine-generated changes or updates to such programs to maintain program effectiveness and engagement. In some embodiments the system uses primary and secondary process flows to collect from the participants information that is used to select or recommend health program modifications.

Analyte monitoring systems and methods for on-body sensor control devices are capable of sensing two or more analytes in a patient and include a processor and memory with instructions for determining various machine states and outputs based on time-correlated sensor data for each analyte. The states and outputs may include warning conditions, advisory messages, corrections to analyte status estimates, indications of sensor control device failure, insulin delivery device failure, drug dose calculations, or analysis reports for one or more analytes. An example system and method is described for dual analytes including glucose and ketones. Data may be transmitted from the sensor control device to a reader for output to a user.

Disclosed is a method for inhibiting the generation of indole ketone of diclofenac in a patch. The patch is a patch having a support layer and an adhesive layer laminated on the support layer, and the method includes a step of mixing diclofenac free acid with an adhesive base to obtain an adhesive composition, and a step of shaping the adhesive composition to obtain the patch. In addition, the content of the diclofenac free acid is 0.5 to 8 mass% based on the total mass of the adhesive layer.

An autobiotic composition includes a prebiotic component and postbiotic component. The prebiotic component is a substance resistant to digestion in the stomach and small intestine and selectively fermentable by microorganisms in the large intestine. The postbiotic component is a short-chain fatty acid, such as butyric acid, lactic acid, succinic acid, or salt or ester thereof, such as tributyrin. An autobiotic composition beneficially combines the microbiome-enhancing effects of a prebiotic with the intestinal healing effects of a postbiotic to provide overall benefits to digestive health. A seedbiotic component may form part of or be co-administered with the autobiotic composition. Enzymes may form part of or be co-administered with the autobiotic composition to enhance digestion of the prebiotic in the stomach and intestine and / or increase microbiome health. An exogenous ketone body component may form part of or be co-administered with the autobiotic composition.

The present invention relates generally to health and fitness. In particular, the present invention relates to a computer-implemented method for optimising a health plan to promote health and fitness and / or weight loss in a subject. The health plan involves monitoring the level of glucose and ketone of the subject over a multi-day time period to provide an indication on whether metabolic switch and / or ketosis is achieved in each day of the multi-day period. Also provided are devices and computer program products as defined herein.

The present invention belongs to the field of drug delivery, and specifically relates to a glucose and ketone body dual-response long-acting insulin delivery system, and a preparation method therefor and the use thereof. The glucose and ketone body dual-response long-acting insulin delivery system provided in the present invention comprises a drug crystal, a polymer coating encapsulating the drug crystal, and a phenylboronic-acid-based cationic polymer modified in the polymer coating. Long-acting insulin can prolong the treatment time of a glucose-responsive insulin delivery carrier and also has ketone body-responsive behavior, thereby inhibiting the occurrence of ketoacidosis. Therefore, problems such as the short treatment time of existing glucose-responsive insulin delivery carriers and the difficulty in constructing ketone body-responsive insulin delivery carriers are solved.

Disclosed are an apparatus, system, processes, and techniques for adapting drug delivery and monitoring a user's safety when the user is experiencing a sick day. A processor may be operable to provide a graphical user interface that presents a sickness mode prompt for a user to indicate that the user or another person with diabetes is sick. The graphical user interface may present symptoms from which a user may select. Based on the selection of symptoms, glucose measurement values, and / or ketone measurement values, a response to the user's indication of sickness may be provided.

A device and method for measuring excreted ketones in a body fluid. The device includes a housing and a sensor positioned within the housing. The sensor includes a body, and a cavity formed in the body, the cavity configured to hold a colorimetric sensing liquid, the body including a ketone permeable medium and a hydrophobic membrane with or without an alkaline material to prevent acidic gases or volatile compound interferents. The sensor is configured to detect presence of ketone in the body fluid in contact with the housing.

The present disclosure relates to a microneedle analyte sensing device for continuous monitoring of an analyte in a user's biological fluid, specifically designed for detecting ketone levels in diabetic ketoacidosis (DKA) management. The disclosed microneedle analyte sensing device utilizes dopamine (DA) molecules covalently linked to the microneedle patch's polymer structure or toluidine blue O (TBO), serving as a redox mediator for measuring the oxidation byproduct of 3-beta-hydroxybutyrate (β-HB). The sensing mechanism relies on catechol-quinone chemistry, where a pre-oxidation approach correlates sensor response to β-HB concentrations. The device comprises a plurality of microneedles on a substrate that, when applied to the skin, penetrate the stratum corneum to contact biological fluid. At least one microneedle functions as a working electrode to detect an electrochemical signal from the enzymatic reaction with the analyte, while additional microneedles serve as counter and reference electrodes to facilitate accurate electrochemical measurements.

In various implementations, berberine metabolites, such as dihydroberberine and / or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and / or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and / or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds.

The invention discloses an adenovirus production culture medium based on metabolism-epigenetic synergistic regulation and application, and relates to the technical field of gene therapy and viral vector production, the culture medium comprises beta-hydroxybutyric acid or salt thereof, alpha-ketoglutaric acid or salt thereof, and L-carnitine or salt thereof. A traditional production process depends on a serum culture medium or a chemical additive, and has the defects of serum dependence, metabolic pressure and mitochondrial function inhibition, epigenetic silencing effect and the like and large-scale production limitation. Through synergistic compatibility of beta-hydroxybutyric acid, alpha-ketoglutaric acid and L-carnitine, ketosome metabolism regulation, epigenetic reprogramming and mitochondrial function enhancement are integrated, the biological bottleneck of a traditional adenovirus production process is broken through, energy supply optimization and epigenetic silencing relief are realized, the process compatibility is improved, and the method is suitable for industrial production. The production efficiency of the adenovirus is greatly improved, and the virus quality is improved.

A method of administering an autobiotic composition that includes a prebiotic component and postbiotic component. The prebiotic component is a substance resistant to digestion in the stomach and small intestine and selectively fermentable by microorganisms in the large intestine. The postbiotic component is a short-chain fatty acid, such as butyric acid, lactic acid, succinic acid, or salt or ester thereof. The prebiotic component is advantageously delivered to the stomach and / or small intestine and the postbiotic is advantageously delivered to the large intestine. A seedbiotic component may form part of or be co-administered with the autobiotic composition. Enzymes may form part of or be co-administered with the autobiotic composition to enhance digestion of the prebiotic in the stomach and intestine and / or increase microbiome health. An exogenous ketone body component may form part of or be co-administered with the autobiotic composition.

The utility model relates to the field of meat transportation, and provides a carcass hanging and fixing device for meat transportation, which comprises a short support, a clamping structure is arranged on the top of the short support, and the clamping structure comprises a servo motor, a gear, a rack, a first sliding block, a first sliding groove, a first connecting rod, a clamping ring and a second connecting rod. The servo motors are installed at the tops of the short supports, gears are arranged outside the servo motors, racks are arranged at the top ends of the gears, first sliding blocks are arranged outside the racks, first sliding grooves are formed in the bottoms of the first sliding blocks, and first connecting rods penetrate through the portions, outside the racks, inside the first sliding blocks. According to the carcass hanging and fixing device, the clamping structure is arranged, the servo motor drives the gear to rotate, the two sets of clamping rings are driven to be close to or away from each other, the bottom of a carcass is clamped, damage caused by bumping and colliding of the carcass in the transportation process is prevented, the carcass hanging and fixing device has the function of stabilizing the carcass, and the stability of the carcass hanging and fixing device is improved.

To provide an analyte sensor for use in detecting ketones.SOLUTION: In certain embodiments, a ketones-responsive active site of a presently disclosed analyte sensor includes an enzyme system comprising β-hydroxybutyrate dehydrogenase and NADH oxidase disposed on a surface of a platinum working electrode. The present disclosure further provides methods for detecting ketones using the disclosed analyte sensors.SELECTED DRAWING: Figure 1A